Table 2.
SGTL2-inhibitor initiation | |
Time from LVAD implantation to SGLT2-inhibitor initiation (n = 34) | 659.3 ± 703 |
SGTL2-inhibitor | |
Canagliflozin | 2 (5.9 %) |
Empagliflozin | 22 (64.7 %) |
Dapagliflozin | 10 (29.4 %) |
Ertugliflozin | 0 (0 %) |
Timing of SGLT2-I initiation | |
Prior to VAD implant | 2 (5.9 %) |
During VAD implant admission | 0 (0 %) |
Post VAD implant admission | 32 (94.1 %) |